Effects of IV Chloride Content on Outcomes
A Comparison of High and Low Chloride Containing IV Fluid Solutions in Patients Undergoing Major Surgery and/or ICU Admission
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Illinois
-
Deerfield, Illinois, United States, 60015
- Baxter Healthcare
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults meeting SIRS criteria receiving at least 500 mL of fluid replacement on day of SIRS.
Exclusion Criteria:
- Receipt of starches or other colloids
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
High Chloride
Patients receiving .9%
sodium choride for resuscitation
|
|
Low chloride
Patients receiving Plasmalyte for resuscitation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: Hospitalization, Expected Length of inpatient stay is approximately 7 days
|
Inpatient mortality.
Expected Length of inpatient stay is approximately 7 days
|
Hospitalization, Expected Length of inpatient stay is approximately 7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Length of Stay
Time Frame: inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days
|
inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days
|
|
Acute renal failure
Time Frame: inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days
|
inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days
|
|
Infections
Time Frame: inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days
|
inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days
|
|
dysrhythmias
Time Frame: inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days
|
inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days
|
|
Electrolyte disorders
Time Frame: inpatient hospitalizationExpected Length of inpatient stay is approximately 7 days
|
inpatient hospitalizationExpected Length of inpatient stay is approximately 7 days
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
readmission
Time Frame: 30, 60 and 90 day
|
30, 60 and 90 day
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- Bax-BSP-HiLoCl
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.